miRNA 511_5p is a potential biomarker for ocular toxoplasmosis.


Journal

Transactions of the Royal Society of Tropical Medicine and Hygiene
ISSN: 1878-3503
Titre abrégé: Trans R Soc Trop Med Hyg
Pays: England
ID NLM: 7506129

Informations de publication

Date de publication:
03 Nov 2023
Historique:
received: 27 04 2023
revised: 23 06 2023
accepted: 30 06 2023
medline: 9 11 2023
pubmed: 21 7 2023
entrez: 21 7 2023
Statut: ppublish

Résumé

Ocular toxoplasmosis (OT) is a frequent clinical manifestation due to infection by Toxoplasma gondii. It is characterized by an inflammatory process involving macrophages activated by pro-inflammatory cytokines. The expression of microRNAs takes place during the inflammatory process and, among them, miRNA 511 regulates the activation of macrophages. This study evaluated the expression of miRNA 511_5p in patients with OT and healthy controls. A total of 361 patients from the Hospital de Base of Fundação Faculdade de Medicina de São José do Rio Preto were enrolled and divided into four groups: G1-patients with active ocular lesions and reagent serology for T. gondii; G2-patients with scars and reagent serology for T. gondii; G3-patients without ocular lesions or scars and reagent serology for T. gondii; G4-patients without ocular lesions or scars and non-reagent serology for T. gondii. All patients underwent clinical and laboratory evaluation to confirm the diagnosis of OT. Serology tests, RNA extraction and cDNA synthesis were performed. The miRNA 511_5p levels were compared among the groups. The G1 group showed a high blood plasma concentration of miRNA 511_5p (mean 22.34) compared with the G2 (4.65), G3 (8.91) and G4 (3.52) groups (p<0.0001). These data suggest that miRNA 511_5p has significant potential as a biomarker for OT.

Sections du résumé

BACKGROUND BACKGROUND
Ocular toxoplasmosis (OT) is a frequent clinical manifestation due to infection by Toxoplasma gondii. It is characterized by an inflammatory process involving macrophages activated by pro-inflammatory cytokines. The expression of microRNAs takes place during the inflammatory process and, among them, miRNA 511 regulates the activation of macrophages. This study evaluated the expression of miRNA 511_5p in patients with OT and healthy controls.
METHODS METHODS
A total of 361 patients from the Hospital de Base of Fundação Faculdade de Medicina de São José do Rio Preto were enrolled and divided into four groups: G1-patients with active ocular lesions and reagent serology for T. gondii; G2-patients with scars and reagent serology for T. gondii; G3-patients without ocular lesions or scars and reagent serology for T. gondii; G4-patients without ocular lesions or scars and non-reagent serology for T. gondii. All patients underwent clinical and laboratory evaluation to confirm the diagnosis of OT. Serology tests, RNA extraction and cDNA synthesis were performed.
RESULTS RESULTS
The miRNA 511_5p levels were compared among the groups. The G1 group showed a high blood plasma concentration of miRNA 511_5p (mean 22.34) compared with the G2 (4.65), G3 (8.91) and G4 (3.52) groups (p<0.0001).
CONCLUSION CONCLUSIONS
These data suggest that miRNA 511_5p has significant potential as a biomarker for OT.

Identifiants

pubmed: 37477502
pii: 7227555
doi: 10.1093/trstmh/trad045
doi:

Substances chimiques

MicroRNAs 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

804-810

Subventions

Organisme : FAPESP
ID : 2018/09448-8
Organisme : CNPq
ID : #305976/2022-2
Organisme : CAPES

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Auteurs

Geraldo Magela de Faria Júnior (GM)

Immunogenetics Laboratory, Molecular Biology Department, Faculdade de Medicina de São José do Rio Preto (FAMERP), 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil; Toxoplasma Research Group, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil.

Laurie Sayuri Kumano (LS)

Immunogenetics Laboratory, Molecular Biology Department, Faculdade de Medicina de São José do Rio Preto (FAMERP), 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil; Toxoplasma Research Group, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil.

Isabela Bronchtein Gomes (I)

Immunogenetics Laboratory, Molecular Biology Department, Faculdade de Medicina de São José do Rio Preto (FAMERP), 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil; Toxoplasma Research Group, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil.

Gláucio Silva Camargos (GS)

Immunogenetics Laboratory, Molecular Biology Department, Faculdade de Medicina de São José do Rio Preto (FAMERP), 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil; Toxoplasma Research Group, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil.

Cristina da Silva Meira-Strejevitch (CDS)

Parasitology and Mycology Center, Adolpho Lutz Institute, 355 Dr Arnaldo Avenue, São Paulo, SP, 01246-000, Brazil.

Lilian Castiglioni (L)

Immunogenetics Laboratory, Molecular Biology Department, Faculdade de Medicina de São José do Rio Preto (FAMERP), 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil; Toxoplasma Research Group, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil.

Mariana Previato (M)

Ophthalmology Outpatient Clinic of Hospital de Base da Fundação Faculdade Regional de Medicina de São José do Rio Preto (HB- FUNFARME), 5544 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil.

Vera Lucia Pereira-Chioccola (VL)

Parasitology and Mycology Center, Adolpho Lutz Institute, 355 Dr Arnaldo Avenue, São Paulo, SP, 01246-000, Brazil.

Cinara Cássia Brandão (CC)

Immunogenetics Laboratory, Molecular Biology Department, Faculdade de Medicina de São José do Rio Preto (FAMERP), 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil; Toxoplasma Research Group, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil.

Luiz Carlos de Mattos (LC)

Immunogenetics Laboratory, Molecular Biology Department, Faculdade de Medicina de São José do Rio Preto (FAMERP), 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, SP, 15090-000, Brazil; Toxoplasma Research Group, Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, SP, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH